Cargando…

Renin–angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease

Hypertension and chronic kidney disease (CKD) are among the most common comorbidities associated with coronavirus disease 2019 (COVID-19) severity and mortality risk. Renin–angiotensin system (RAS) blockers are cornerstones in the treatment of both hypertension and proteinuric CKD. In the early mont...

Descripción completa

Detalles Bibliográficos
Autores principales:	Theodorakopoulou, Marieta P, Alexandrou, Maria-Eleni, Boutou, Afroditi K, Ferro, Charles J, Ortiz, Alberto, Sarafidis, Pantelis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754739/ https://www.ncbi.nlm.nih.gov/pubmed/35198155 http://dx.doi.org/10.1093/ckj/sfab272

Ejemplares similares

Nailfold Capillaroscopy in Systemic Sclerosis Patients with and without Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
por: Minopoulou, Ioanna, et al.
Publicado: (2021)

Hypertension in kidney transplant recipients
por: Alexandrou, Maria-Eleni, et al.
Publicado: (2022)

Non-Invasive Assessment of Endothelial Dysfunction in Pulmonary Arterial Hypertension
por: Dara, Athanasia, et al.
Publicado: (2021)

Renal artery stenting in the correct patients with atherosclerotic renovascular disease: time for a proper renal and cardiovascular outcome study?
por: Theodorakopoulou, Marieta P, et al.
Publicado: (2022)

Kidney transplantation improving cardiopulmonary exercise responses: still some way to go before conclusive evidence
por: Boutou, Afroditi, et al.
Publicado: (2020)

Endothelial dysfunction in COPD: a systematic review and meta-analysis of studies using different functional assessment methods
por: Theodorakopoulou, Marieta P., et al.
Publicado: (2021)

Nocturnal dipping profile in chronic kidney disease: Searching for underlying mechanisms in order to prevent adverse events
por: Theodorakopoulou, Marieta, et al.
Publicado: (2020)

A parallel evaluation of short- and mid-term changes of ambulatory blood pressure in kidney transplant recipients and kidney donors
por: Xagas, Efstathios, et al.
Publicado: (2022)

Impact of public restrictive measures on hypertension during the COVID-19 pandemic: existing evidence and long-term implications
por: Karagiannidis, Artemios G, et al.
Publicado: (2022)

The effect of standard percutaneous nephrolithotomy, miniaturized percutaneous nephrolithotomy and retrograde intrarenal surgery on biomarkers of renal injury: a randomized clinical trial
por: Memmos, Dimitrios, et al.
Publicado: (2023)

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020)

Ambulatory blood pressure trajectories and blood pressure variability in kidney transplant recipients: a comparative study against chronic kidney disease patients
por: Korogiannou, Maria, et al.
Publicado: (2022)

Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney
por: Jiang, Xiao, et al.
Publicado: (2020)

Peridialytic and intradialytic blood pressure metrics are not valid estimates of 44-h ambulatory blood pressure in patients with intradialytic hypertension
por: Theodorakopoulou, Marieta P., et al.
Publicado: (2022)

Ambulatory blood pressure trajectories and blood pressure variability in kidney transplant recipients: a comparative study against haemodialysis patients
por: Korogiannou, Maria, et al.
Publicado: (2021)

Renin-angiotensin system blockers and COVID-19
por: Vidal-Petiot, Emmanuelle, et al.
Publicado: (2021)

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
por: Heerspink, H. J. L., et al.
Publicado: (2016)

Effect of renin-angiotensin system blocker on COVID-19 in young patients with hypertension
por: Kuzeytemiz, Mustafa, et al.
Publicado: (2022)

Renin-Angiotensin System - Considerations for Hypertension and Kidney
por: Yim, Hyung Eun, et al.
Publicado: (2008)

Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension
por: Wei, Jie, et al.
Publicado: (2019)

Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension
por: Moon, Ju-Young
Publicado: (2013)

Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease
por: Huang, Rong-Shuang, et al.
Publicado: (2016)

Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis
por: Morishita, Yoshiyuki, et al.
Publicado: (2014)

Fixed-Dose Combinations of Renin–Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors
por: Hsiao, Fu-Chih, et al.
Publicado: (2015)

Endothelial and microvascular function in liver cirrhosis: an old concept that needs re-evaluation?
por: Papagiouvanni, Ioanna, et al.
Publicado: (2022)

Assessment of Oxidative Stress Markers in Hypertensive Patients under the Use of Renin-Angiotensin-Aldosterone Blockers
por: Vazquez-Agra, Nestor, et al.
Publicado: (2023)

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
por: Mancia, Giuseppe, et al.
Publicado: (2020)

Atherosclerotic renovascular disease: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) and the Working Group Hypertension and the Kidney of the European Society of Hypertension (ESH)
por: Sarafidis, Pantelis A, et al.
Publicado: (2023)

Updates on the Treatment of Essential Hypertension: A Summary of AHRQ’s Comparative Effectiveness Review of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Direct Renin Inhibitors
por: Powers, Benjamin, et al.
Publicado: (2011)

Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
por: Farid fahmy, Sarah, et al.
Publicado: (2023)

The renin–angiotensin system and diabetes: An update
por: Ribeiro-Oliveira, Antônio, et al.
Publicado: (2008)

Renin Angiotensin System Blockers and Risk of Mortality in Hypertensive Patients Hospitalized for COVID-19: An Italian Registry
por: Angeli, Fabio, et al.
Publicado: (2022)

Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II–Renin Feedback in Hypertensive Patients
por: Kawabata, Yutaka, et al.
Publicado: (2020)

Association of Renin-Angiotensin System Blockers With Outcomes in Patients with COVID-19
por: Garg, Aakash, et al.
Publicado: (2020)

Association of Renin-Angiotensin System Blockers with Survival in Patients on Maintenance Hemodialysis
por: Kang, Seok Hui, et al.
Publicado: (2023)

Protection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease
por: Shen, Jian, et al.
Publicado: (2016)

Renin-angiotensin-aldosterone system blockers in Bulgarian COVID-19 patients with or without chronic kidney disease
por: Filev, Rumen, et al.
Publicado: (2022)

Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic
por: Chen, Hongyin, et al.
Publicado: (2023)

Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)
por: Sarafidis, Pantelis, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_peiuh9rvlhmtccr57ktnlsumkr